Literature DB >> 34993850

Similar Gut Hormone Secretions Two Years After One Anastomosis Gastric Bypass and Roux-en-Y Gastric Bypass: a Pilot Study.

Claire Carette1,2, Johanne Le Beyec3,4, David De Bandt1, Claire Rives-Lange1, Yvann Frigout5,2, Damien Bergerot2, Anne Blanchard2, Maude Le Gall6, Jean-Marc Lacorte7, Jean-Marc Chevallier8, Sébastien Czernichow1, Tigran Poghosyan8.   

Abstract

OBJECTIVES: One-anastomosis gastric bypass (OAGB) is as effective as Roux-en-Y gastric bypass (RYGB) regarding weight loss and diabetes remission. However, there are no data on gut hormone secretions after OAGB. The aim of this study was to compare fasting and postprandial secretions of gut and pancreatic hormones in OAGB versus RYGB patients. DESIGN AND METHODS: Twenty-nine patients, 16 OAGB- and 13 RYGB-operated, underwent a liquid mixed-meal tolerance test at 2 years' post-surgery. Blood was sampled before and 15, 30, 60, 90, and 120 min after meal for plasma measurement of glucose, C-peptide, insulin, glucagon, GLP-1, GIP, GLP-2, PYY, and ghrelin.
RESULTS: Percentage of total weight loss 2 years post-surgery were -33.9 ± 1.8% for OAGB and -31.2 ± 1.6% for RYGB (p = 0.6). Four patients with persistent diabetes were excluded for further analysis. Fasting and postprandial glucose levels (peaks and area under curve values) were similar between groups. HOMA index was lower in the OAGB group (0.8 ± 0.1 vs 1.3 ± 0.2 in RYGB, p < 0.05). Levels of C-peptide (or insulin) measured at 30 min were significantly lower in OAGB vs RYGB patients (6.9 ± 0.5 vs 9.7 ± 1.1 µg/l, p < 0.05). No difference was observed between OAGB and RYGB groups for GLP-1, GLP-2, PYY, or ghrelin postprandial secretions, but GIP tended to be lower in OAGB vs RYGB patients (756 ± 155 vs 1100 ± 188 pg/ml for postprandial peak concentrations, p = 0.06).
CONCLUSIONS: This is the first clinical study showing that OAGB procedure, like RYGB, results in high postprandial secretions of gut hormones, in particular GLP-1. TRIAL REGISTRATION: Clinical Trials NCT03482895.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  GIP; GLP-1; Gut hormones; One anastomosis gastric bypass; Roux-en-Y gastric bypass

Mesh:

Substances:

Year:  2022        PMID: 34993850     DOI: 10.1007/s11695-021-05837-5

Source DB:  PubMed          Journal:  Obes Surg        ISSN: 0960-8923            Impact factor:   4.129


  15 in total

Review 1.  Impact of Bariatric Surgery on Metabolic and Gut Microbiota Profile: a Systematic Review and Meta-analysis.

Authors:  Dimitrios E Magouliotis; Vasiliki S Tasiopoulou; Eleni Sioka; Christina Chatedaki; Dimitrios Zacharoulis
Journal:  Obes Surg       Date:  2017-05       Impact factor: 4.129

2.  One Anastomosis Gastric Bypass Versus Roux-en-Y Gastric Bypass for Morbid Obesity: an Updated Meta-Analysis.

Authors:  Dimitrios E Magouliotis; Vasiliki S Tasiopoulou; George Tzovaras
Journal:  Obes Surg       Date:  2019-09       Impact factor: 4.129

Review 3.  Intestinal adaptations following bariatric surgery: towards the identification of new pharmacological targets for obesity-related metabolic diseases.

Authors:  Lara Ribeiro-Parenti; Jean-Baptiste Cavin; Maude Le Gall
Journal:  Curr Opin Pharmacol       Date:  2017-08-17       Impact factor: 5.547

4.  Efficacy and safety of one anastomosis gastric bypass versus Roux-en-Y gastric bypass for obesity (YOMEGA): a multicentre, randomised, open-label, non-inferiority trial.

Authors:  Maud Robert; Philippe Espalieu; Elise Pelascini; Robert Caiazzo; Adrien Sterkers; Lita Khamphommala; Tigran Poghosyan; Jean-Marc Chevallier; Vincent Malherbe; Elie Chouillard; Fabian Reche; Adriana Torcivia; Delphine Maucort-Boulch; Sylvie Bin-Dorel; Carole Langlois-Jacques; Dominique Delaunay; François Pattou; Emmanuel Disse
Journal:  Lancet       Date:  2019-03-06       Impact factor: 79.321

5.  The Effects of One-Anastomosis Gastric Bypass on Glucose Metabolism in Goto-Kakizaki Rats.

Authors:  Lorea Zubiaga; Rafael Abad; Jaime Ruiz-Tovar; Pablo Enriquez; Juan Antonio Vílchez; Mireia Calzada; José Antonio Pérez De Gracia; Mervyn Deitel
Journal:  Obes Surg       Date:  2016-11       Impact factor: 4.129

6.  Roux-en-Y gastric bypass corrects hyperinsulinemia implications for the remission of type 2 diabetes.

Authors:  Melissa A Reed; Walter J Pories; William Chapman; John Pender; Rita Bowden; Hisham Barakat; Timothy P Gavin; Tom Green; Ed Tapscott; Donghai Zheng; Nigel Shankley; Lynn Yieh; David Polidori; Steven P Piccoli; Leona Brenner-Gati; G Lynis Dohm
Journal:  J Clin Endocrinol Metab       Date:  2011-05-18       Impact factor: 5.958

7.  Incretin levels 1 month after laparoscopic single anastomosis gastric bypass surgery in non-morbid obese type 2 diabetes patients.

Authors:  Myung Jin Kim; Hyeong Kyu Park; Dong Won Byun; Kyo Il Suh; Kyung Yul Hur
Journal:  Asian J Surg       Date:  2013-11-06       Impact factor: 2.767

8.  Laparoscopic sleeve gastrectomy versus single anastomosis (mini-) gastric bypass for the treatment of type 2 diabetes mellitus: 5-year results of a randomized trial and study of incretin effect.

Authors:  Wei-Jei Lee; Keong Chong; Yu-Hung Lin; Jih-Hua Wei; Shu-Chun Chen
Journal:  Obes Surg       Date:  2014-09       Impact factor: 4.129

Review 9.  Leveraging the Gut to Treat Metabolic Disease.

Authors:  Ruth E Gimeno; Daniel A Briere; Randy J Seeley
Journal:  Cell Metab       Date:  2020-03-17       Impact factor: 27.287

10.  Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations.

Authors:  Francesco Rubino; David M Nathan; Robert H Eckel; Philip R Schauer; K George M M Alberti; Paul Z Zimmet; Stefano Del Prato; Linong Ji; Shaukat M Sadikot; William H Herman; Stephanie A Amiel; Lee M Kaplan; Gaspar Taroncher-Oldenburg; David E Cummings
Journal:  Diabetes Care       Date:  2016-06       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.